Bionomics Limited (BNOX)
NASDAQ: BNOX · Real-Time Price · USD
0.280
+0.010 (3.67%)
Oct 11, 2024, 4:00 PM EDT - Market closed
Bionomics Revenue
Bionomics had revenue of $-48.43K in the quarter ending June 30, 2024, with 9.59% growth.
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
4.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Integrated Sciences | 13.52M |
Exicure | 500.00K |
Silo Pharma | 72.10K |
Cardio Diagnostics Holdings | 39.14K |
Titan Pharmaceuticals | 3.00K |
BNOX News
- 12 days ago - Bionomics Limited announces intention to re-domicile to the United States - GlobeNewsWire
- 5 weeks ago - Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - GlobeNewsWire
- 2 months ago - Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 - GlobeNewsWire
- 3 months ago - Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder - GlobeNewsWire
- 4 months ago - Bionomics Limited Announces Private Placement of up to $70.0 Million - GlobeNewsWire
- 5 months ago - Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting - GlobeNewsWire
- 7 months ago - Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - GlobeNewsWire